| Wednesday, February 15, 2012 |
|
|
8:00 am to 8:30 am |
Morning lecture |
| Session 1: |
10:30 am to 10:30 am |
Lipotoxicity in diabetes |
| Session 2: |
11:00 am to 1:00 pm |
Immunobiology of lipotoxicity |
| Session 3: |
2:30 to 4:30 pm |
Therapeutic beta cells |
| Evening: |
5:00 to 8:00 pm |
Welcome dinner, lecture, and presentation of award winners |
| |
|
|
| Thursday, February 16, 2012 |
|
|
8:00 am to 8:30 am |
Morning lecture |
| Session 1: |
8:30 to 10:30 am |
Controversies in diabetes immunology (1) |
| Session 2: |
11:00 am to 1:00 pm |
Controversies in diabetes immunology (2) |
| Debate: |
2:30 to 3:30 pm |
Insufficient biomarkers and endpoints doomed recent Phase III clinical trials |
| Session 3: |
4:00 to 6:00 pm |
Advances in islet transplantation |
| Evening: |
6:00 to 8:00 pm |
Poster session |
| |
|
|
| Friday, February 17, 2012 |
|
| Session 1: |
8:00 to 10:00 am |
Obesity and bariatric surgery |
| Session 2: |
10:30 am to 12:30 pm |
Advances in diabetes complications |
| Debate: |
1:30 pm to 2:30 pm |
Type 1 diabetes is an autoimmune disease |
| Session 3: |
3:00 pm to 5:00 pm |
Beta cell development |
| Session 4: |
5:30 pm to 7:30 pm |
Islet imaging |
|
|
|
|
|
| Saturday, February 18, 2012 |
|
|
8:00 am to 8:50 am |
Morning lectures |
| Session 1: |
8:50 to 10:25 am |
New technologies and insulins for type 1 diabetes |
| Session 2: |
10:45 am to 12:45 pm |
Major controversies in clinical diabetology |
| Session 3: |
1:00 to 3:00 pm |
Incretin therapy |
